MW073 is a serotonin 5-HT2B receptor antagonist which is used in scientific research. It is a highly selective antagonist of the serotonin 5-HT2B receptor. The drug is orally active in animals and is said to have a favorable drug-like profile. It produces antiaggressive effects without causing sedation or altering locomotor activity or anxiety in an animal model of Alzheimer's disease. Similarly, it produces neuroprotective, neurorestorative, and pro-cognitive-like effects in such models. MW073 was first described in the scientific literature by 2024. There is interest in MW073 for the potential treatment of Alzheimer's disease and other conditions.
See also List of investigational aggression drugs Minaprine
References


